CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
View Top Employees from CSL| Website | https://www.csl.com/ |
| Ticker | CSL |
| Revenue | $10.6 billion |
| Employees | 21,826 (9,008 on RocketReach) |
| Founded | 1916 |
| Address | 655 Elizabeth St, Melbourne, Victoria 3000, AU |
| Fax | +61 3 9389 1434 |
| Industry | Biotechnology Research, Pharmaceuticals, Complex biologicals, Healthcare, Vaccines, Plasma And Plasma Derived Therapeutics |
| Keywords | Plasma, Dialysis Treatment, Immunology |
| Competitors | Baxter International Inc., Bristol Meyers Squibb, Genentech, Grifols, Regeneron |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular CSL employee's phone or email?
CSL Questions
The CSL annual revenue was $10.6 billion in 2024.
Joy Linton is the CFO of CSL.
9,008 people are employed at CSL.
CSL is based in Melbourne, Victoria.
The NAICS codes for CSL are [3254, 32541, 325, 32].
The SIC codes for CSL are [283, 28].
Top CSL Employees
-
Joy Linton
Chief Financial Officer at CSL
Melbourne, VIC, AU2 -
Michael Wilson
Vice President Research at CSL
Melbourne, VIC, AU1 -
Brian Fehrer
Vice President, Talent at CSL
Philadelphia, Pennsylvania, United States35 -
Jonathan Edelman
Senior Vice President, Vaccines Innovation Unit, CSL R&D at CSL
Philadelphia, PA, US45+ -
Daniel Smith
Head of Technology at CSL
London, GB51
Related Companies
